

### 4.0.3 DOC Cmte minutes

#### **Parkinson's disease guideline committee meeting**

**Date:** 21/01/2016

**Location:** Bollin, NICE Offices Manchester, Piccadilly Plaza, M1 4BT

**Minutes:** Draft

<b>Committee members present:</b>	
Paul Cooper (Chair)	Present for all
Janine Barnes (JB)	Present for all
Alistair Church (AC)	Present for all
Debbie Davies (DD)	Present for all
Julian Evans (JE)	Present for items 2 - 4
Robin Fackrell (RF)	Present for all
Richard Grunewald (RG)	Present for all
Fiona Lindop (FL)	Present for items 1 - 6
Jane Little (JL)	Present for all
Lynne Osbourne (LO)	Present for all
Paul Shotbolt	Present for all
Matthew Sullivan (MS)	Present for all
Richard Walker (RW)	Present for all

<b>In attendance:</b>		
Gabriel Rogers (GR)	Technical Adviser – Health Economics	Present for all
Steven Ward (SW)	Health Economist	Present for all
Sue Spiers (SS)	Associate Director	Present for items 1 - 4
Sarah Mills (SM)	Project Manager	Present for all

### 4.0.3 DOC Cmte minutes

Aimely Lee (AL)	Technical Analyst	Present for all
Kate Moring (KM)	Business Analyst	Present for items 2-4 & 8
Louise Bate	Associate Director – Medicines Education	Present for items 5 & 6

#### Observers:

None	
------	--

#### Committee member apologies:

Graham Lennox	Committee member
Ivan Bennett	Committee member

### 1. Welcome, introductions, minutes, DoI and matters arising

The Chair welcomed the Committee members and attendees to the ninth meeting on Parkinson's disease.

The Chair asked those present to declare any conflicts of interest relevant to the areas being discussed or potential new conflicts.

Name	Declaration	Classification	Chairs action
Paul Cooper (PC)	Member of the American Epilepsy Society guideline committee.	Non-specific, personal, non-financial	Declare and participate
	Association of British Neurologists, committee member of specialist advisory group	Non-specific, personal, non-financial	Declare and participate
	European Academy of Neurology Scientific Panel – Brain Injury committee	Non-specific, personal, non-financial	Declare and participate

#### 4.0.3 DOC Cmte minutes

<p>Fiona Lindop</p>	<p>A lecture to the Association of Physiotherapists with an Interest in neurology (ACPIN) in Norwich in November entitled "European Guidelines and Physiotherapy Management in Parkinson's". I was paid a fee of £250 for this.</p> <p>I am on the Parkinson's UK Excellence Network National Oversight Board (representing therapy) and am also a member of the Service Development Group for this Network.</p> <p>I represent Physiotherapy on the Parkinson's UK National Audit of the NICE Guidelines for Parkinson's which is due to report the 2015 Audit later this year.</p>	<p>Specific, personal, financial (non-commercial sector)</p> <p>Specific, personal, non-financial</p> <p>Specific, personal, non-financial</p>	<p>Declare and participate</p> <p>Declare and participate</p> <p>Declare and participate</p>
<p>Janine Barnes</p>	<p>Member of 2 Parkinson's UK Excellence committees:</p> <p>Evidence based practice and development of a medicines management standard to be a statement of good practice.</p>	<p>Specific, personal, non-financial</p>	<p>Declare and participate</p>

#### 4.0.3 DOC Cmte minutes

Matthew Sullivan	Member of the Parkinson's UK Research Support Development Team.  Member of Parkinson's UK Excellence Network – preparation of training materials for lay members.	Specific, personal, non – financial (honoraria in line with NICE lay member payments)  Specific, personal, non-financial (honoraria paid in line with NICE lay members payments)	Declare and participate  Declare and participate
Richard Walker	Parkinson's UK Excellence network – lead on care homes and ethnic minority groups	Specific, personal, non-financial	Declare and participate
Richard Grunewald	Presentation of UCB funded lecture on clozapine at the Yorkshire Movement disorder group (honorary donated to Parkinsons UK)	Specific, personal, non-financial	Declare and participate

It was agreed that all committee members were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.

The committee reviewed the minutes of the previous meeting and agreed they were an accurate record of the discussions.

#### 4.0.3 DOC Cmte minutes

The Chair updated the committee on the impact of NHS England's policy on Duodopa on the development of the Parkinson's Disease guideline.

PC confirmed that the main objectives for the day were to agree health economic modelling inputs and consider evidence for review question 21.

#### **2. Approach to data in advanced PD stage review questions**

The committee considered the relevance of data from the PDSurg RCT for the review questions around advanced PD interventions. Agreement was reached as to what type of data analysis would be of most value clinically.

#### **3 & 4. Health Economic modelling for advanced PD discussions**

The committee considered modelling inputs including, model structure and transitions, cost input and queries and quality of life inputs and queries. The committee agreed the assumptions which will be built into the health economic model.

#### **5 & 6. Review Question 21 - What is the comparative effectiveness of antipsychotics for the treatment of symptoms of psychosis associated with Parkinson's disease?**

AL & GR presented evidence for review question 21, including a network meta-analysis. The committee discussed the evidence and made draft recommendations based on the evidence presented and their clinical experience and expertise.

#### **7. Review protocols**

SW reported that the Medicines & Prescribing team had made some amendments to the review protocols for questions 14&19. The committee considered these amendments and made some further minor changes before agreeing the amended protocols.

RQ 14 - What is the comparative effectiveness of levodopa preparations, monoamine oxidase B inhibitors, dopamine agonists and anticholinergics as first-line treatment of motor symptoms?

RQ 19 - What is the comparative effectiveness of pharmacological interventions as

#### 4.0.3 DOC Cmte minutes

adjuvants to levodopa preparations?

#### 8. Costing

KM gave a presentation outlining the role of the resource impact assessment team and notified the committee that they would be seeking volunteers to assist with the costing work towards the end of the guideline development.

#### 9. AOB.

The Chair thanked the group for their attendance and contributions.

SM confirmed the dates of the next meeting, advised that the LETR tables and chapters will be circulated for information and comment and confirmed the date and location of the next meeting.

**Date of next meeting:** 10 & 11 March 2016

**Location of next meeting:** External venue, Manchester